From: Developing Gram-negative bacteria for the secretion of heterologous proteins
Secretion system | Mechanism | Secretion product | Product type | Extracellular titer | References |
---|---|---|---|---|---|
Type I | HlyA | scFv | Antibody | 2 mg/L | [68] |
Type I | HlyA | CGTase | Industrial | 0.58 mg/L | [124] |
Type I | HlyA | Cutinase | Industrial | 334 U/mL | [69] |
Type I | HlyA | Interferon alpha 2 | Therapeutic | 6 mg/L | [37] |
Type I | TliDEF, HlyA | Lipase | Industrial | 8450 U/mL, 3 mg/L | |
Type I | TliDEF | Metalloprotease | Industrial | 789 mg/L | [62] |
Type I | TliDEF | Endo-β-1,4-mannanase | Industrial | 4.65 mg/L | [75] |
Type II and generalized two-step | TatExpress | hGH | Therapeutic | 30 mg/L | [60] |
TatExpress | scFv | Antibody | N/A* | [60] | |
Type II and generalized two-step | Periplasmic expression via SRP | IgG | Antibody | 236.5 mg/L | [96] |
Type II and generalized two-step | Leaky OM | Human parathyroid hormone | Therapeutic | 680 mg/L | [36] |
Type II and generalized two-step | Leaky OM | Fab | Antibody | 6 g/L | [125] |
Type II and generalized two-step | Leaky OM | IFN-α | Therapeutic | N/A* | [95] |
Type II and generalized two-step | Unknown, Cel-CD fusion | CGTase | Industrial | 637.4 U/ml, 348 mg/L | |
Type II and generalized two-step | Cel-CD fusion | Carbohydrate binding domain | Industrial | 348 mg/L | [34] |
Type II and generalized two-step | Cel-CD fusion | Neuritin | Therapeutic | 211 mg/L | [34] |
Type II and generalized two-step | YebF | α-amylase | Industrial | 150 µmol glucose/min/mg protein | [54] |
Type II and generalized two-step | YebF | Interleukin-2 | Therapeutic | 43,800 U/mL | [101] |
Type II and generalized two-step | YebF | NanH2 Sialidase | Therapeutic | N/A* | [126] |
Type II and generalized two-step | OsmY | Human leptin | Therapeutic | 250 mg/L | [102] |
Type II and generalized two-step | OsmY | Osteopontin | Therapeutic | 3.6 mg/L | [100] |
Type III | Flagellar | Interferon alpha 2 | Therapeutic | 0.6 mg/L | [50] |
Type III | Flagellar | Lipase | Industrial | ~420 U/L | [127] |
Type III | Flagellar | Enfuvirtide | Therapeutic | 13.4 mg/L | [128] |
Type III | Flagellar | Apical membrane antigen 1 | Therapeutic | N/A* | [89] |
Type III | Flagellar | δ-SVIE | Therapeutic | N/A* | [89] |
Type III | Flagellar | MrVIA | Therapeutic | N/A* | [89] |
Type III | Flagellar | NCR peptide | Therapeutic | N/A* | [89] |
Type III | Injectisome | Spider silk monomer | Material | 14 mg/L | [27] |
Type III | Injectisome | Elastin | Material | 20 mg/L | [27] |
Type III | Injectisome | Resilin | Material | 20 mg/L | [27] |
Type V | Type V | Pertactin | Therapeutic | 1 mg/L | [39] |
Type V | Type V | Ag85B | Therapeutic | N/A* | [39] |
Type VIII | Type VIII | sdAb | Antibody | N/A* | [114] |
Type VIII | Type VIII | Cecropin A | Therapeutic | 294 mg/L (after purification) | [115] |
Type VIII | Type VIII | Mussel foot protein | Material | N/A* | [117] |